BioNTech SE (BNTX)
Automate Your Wheel Strategy on BNTX
With Tiblio's Option Bot, you can configure your own wheel strategy including BNTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BNTX
- Rev/Share 11.4264
- Book/Share 78.747
- PB 1.15
- Debt/Equity 0.0155
- CurrentRatio 10.1828
- ROIC -0.0659
- MktCap 21769128897.8738
- FreeCF/Share -4.8543
- PFCF -18.6586
- PE -28.316
- Debt/Assets 0.0138
- DivYield 0
- ROE -0.0402
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Reiterated | BNTX | H.C. Wainwright | -- | Buy | $134 | $145 | June 5, 2025 |
| Initiation | BNTX | Goldman | -- | Neutral | -- | $110 | May 29, 2025 |
| Initiation | BNTX | Citigroup | -- | Buy | -- | $145 | March 13, 2025 |
| Initiation | BNTX | Truist | -- | Buy | -- | $172 | Jan. 10, 2025 |
| Initiation | BNTX | Wells Fargo | -- | Overweight | -- | $170 | Dec. 11, 2024 |
| Upgrade | BNTX | Morgan Stanley | Equal Weight | Overweight | $93 | $145 | Sept. 24, 2024 |
| Upgrade | BNTX | Jefferies | Hold | Buy | $96 | $150 | Sept. 17, 2024 |
| Upgrade | BNTX | JP Morgan | Underweight | Neutral | $91 | $125 | Sept. 16, 2024 |
News
CureVac Stock Soars on BioNTech Buyout
Published: June 12, 2025 by: Schaeffers Research
Sentiment: Positive
Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.
Read More
BioNTech boosts cancer mRNA pipeline with CureVac acquisition
Published: June 12, 2025 by: Proactive Investors
Sentiment: Positive
BioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA vaccine developer, in an all-stock deal valued at approximately $1.25 billion. Under the deal terms, each share of CureVac will be exchanged for about $5.46 worth of BioNTech American Depositary Shares (ADSs), representing a premium of around 55% over CureVac's recent trading price.
Read More
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
Published: June 10, 2025 by: Reuters
Sentiment: Neutral
Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccine panel late on Monday.
Read More
Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment
Published: June 06, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb is attractively valued, offers a 5%+ dividend yield, and benefits from a strong oncology pipeline after its BioNTech deal. The $11B BioNTech partnership gives BMY access to BNT327, targeting large cancer markets, with a deal structure that limits BMY's downside risk. BMY's established cash flows, low payout ratio, and current low valuation make it a safer, income-generating pick versus higher-risk, growth-oriented BioNTech.
Read More
Bristol Myers Collaborates With BNTX for Oncology Candidate
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid tumors.
Read More
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Published: June 02, 2025 by: CNBC Television
Sentiment: Neutral
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Read More
Bristol Myers Squibb CEO on $11B cancer drug deal with BioNTech
Published: June 02, 2025 by: CNBC Television
Sentiment: Positive
Christopher Boerner, CEO of Bristol Myers Squibb, said Monday that the company's $11 billion cancer drug partnership with BioNTech could be "the next new frontier in the treatment of cancer." The companies will work on transforming outcomes for patients with difficult-to-treat solid tumors, Boerner said.
Read More
Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer
Published: June 02, 2025 by: CNBC Television
Sentiment: Positive
Christopher Boerner, Bristol Myers CEO, joins 'Squawk on the Street' to discuss the company's recent partnership with Biontech, the cost of the deal and much more.
Read More
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race
Published: June 02, 2025 by: Market Watch
Sentiment: Positive
Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug game.
Read More
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
MAINZ, Germany, and PRINCETON, USA, June 2, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work jointly to broaden and accelerate the development of this clinical candidate.
Read More
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.
Read More
BioNTech plans up to $1.33 billion investment in the United Kingdom
Published: May 20, 2025 by: Reuters
Sentiment: Positive
German vaccine maker BioNTech said on Tuesday that it plans to invest up to 1 billion pounds ($1.33 billion) over the next ten years to broaden its research and development activities in the United Kingdom.
Read More
BioNTech: mRNA Challenges Amid Regulatory Uncertainty (Rating Downgrade)
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Negative
BioNTech maintains strong cash reserves (€15.85B) despite widening losses as COVID revenues decline and R&D expenses increase. BNT327 (PD-L1/VEGF-A bispecific) advances to Phase 3 trials, but shares dropped after competitor's interim data disappointed investors. Increased regulatory scrutiny under Kennedy's HHS creates uncertainty for mRNA technologies, prompting a downgrade from Buy to Hold.
Read More
BioNTech SE (BNTX) Q1 2025 Earnings Call Transcript
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral
BioNTech SE (NASDAQ:BNTX ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Co-Founder & Chief Executive Officer Özlem Türeci - Co-Founder & Chief Medical Officer Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Akash Tewari - Jefferies Daina Graybosch - Leerink Partners Cory Kasimov - Evercore Terence Flynn - Morgan Stanley Jessica Fye - JPMorgan Evan Seigerman - BMO Capital Markets Yaron Werber - TD Cowen Mohit Bansal - Wells Fargo Harry Gillis …
Read More
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Published: March 31, 2025 by: Fast Company
Sentiment: Negative
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr. over his views on immunization.
Read More
Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs and Therapeutics Seagen
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Dublin, March 20, 2025 (GLOBE NEWSWIRE) -- The "Refractory Metastatic Melanoma - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Refractory Metastatic Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Refractory Metastatic Melanoma R&D. …
Read More
BioNTech SE (BNTX) Q4 2024 Earnings Call Transcript
Published: March 10, 2025 by: Seeking Alpha
Sentiment: Neutral
BioNTech SE (NASDAQ:BNTX ) Q4 2024 Earnings Conference Call March 10, 2025 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Co-Founder and Chief Executive Officer Ozlem Tureci - Co-Founder and Chief Medical Officer Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Akash Tewari - Jefferies Chris Shibutani - Goldman Sachs Tazeen Ahmad - Bank of America Securities Terence Flynn - Morgan Stanley Harry Gillis - Berenberg Cory Kasimov - Evercore Sadia Rahman - Wells Fargo Asthika Goonewardene - Truist Securities Yaron Werber …
Read More
BioNTech Stock Drops as Sales Outlook Disappoints
Published: March 10, 2025 by: Investopedia
Sentiment: Negative
U.S.-listed shares of BioNTech (BNTX) lost ground Monday, as the COVID-19 vaccine maker's soft outlook for the year offset better-than-expected quarterly results.
Read More
What Makes BioNTech (BNTX) a New Buy Stock
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
BioNTech (BNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
About BioNTech SE (BNTX)
- IPO Date 2019-10-10
- Website https://www.biontech.de
- Industry Biotechnology
- CEO Dr. Ugur Sahin M.D.
- Employees 6772